Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 296

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 296
---
 |       |    127 | % |     |       |     82 | % |     |       |     60 | % |     |       |     28 | % |     |       |     15 | % |     |       |      8 | % |     |       |      5 | % |
| Lumee Glucose           |     | $     | — |     | $     |  0.96 |     | $     | 57.07 |   |     | $     | 174.22 |   |     | $     | 308.46 |   |     | $     | 502.75 |   |     | $     | 703.86 |   |     | $     | 844.63 |   |     | $     | 929.09 |   |     | $     | 975.54 |   |
| Annual growth rate (%)  |     |       |   |     |       |       |     |       | 5,873 | % |     |       |    205 | % |     |       |     77 | % |     |       |     63 | % |     |       |     40 | % |     |       |     20 | % |     |       |     10 | % |     |       |      5 | % |

The list below provides a further explanation of the assumptions included in the Updated Projections: Revenue Assumptions •Regarding the revenue assumptions for Lumee Oxygen, Profusa’s management assumed that the Company will attain regulatory approval in the US by late 2026, with commercialization in EU based on the CE approval and successful MDR transition in EU by Q4 2025. It is estimated that the time from approval to commercial availability will be approximately one quarter for each product with associated revenue from distributor stocking orders. This assumption was based on discussions with contract manufacturing partners and Profusa’s management’s past experience. •Revenue forecasts were based on a compilation of market data from various sources for both PAD/CLI management in the case of the Lumee Oxygen product, and diabetes prevalence and market size for the Lumee Glucose product. The sources of market size and market growth information include: Academic publications, the American Diabetes Association, US and EU census bureaus as well as other relevant sources. 1,2,3Penetration rates for each addressable market were estimated by applying range of sizes of patient volume